Aug. 17, 2014; Charlotte, NC; Chiefs DT Kyle Love (94) before the second preseason game against the Carolina Panthers. Photo used with permission by Chiefs PR. Credit: KCChiefs.com
KANSAS CITY, Mo. – Chiefs defensive tackle Kyle Love normally tackles opposing offensive players.
But the 6-1, 315-pound defender has decided to tackle a cause close to his heart.
Love, who has Type 2 diabetes, agreed to join Seattle Seahawks quarterback Russell Wilson and defensive tackle Jordan Hill to support CR3 Diabetes Association, Inc., Love’s agent, Richard Kopelman of Klass Sports, LLC, announced Tuesday evening.
“I am very proud to be a part of Team CR3,” Love said in a statement. “I feel that Russell, Jordan and myself, together we all can make a huge impact for CR3 Diabetes Association, Inc. to help more diabetics.”
Wilson, who lost his father to complications of diabetes, serves as the organization’s national ambassador. Love will serve with Hill, whose father has diabetes, as CR3 team members.
The CR3 Diabetes Association, Inc. is a 501(c)3 non-profit organization with a mission “to make a difference in the lives of people living with diabetes all over the world by providing equipment and encouragement to those in need,” according to its official website, www.cr3diabetes.org.
The organization also assists in providing “free and affordable supplies to uninsured diabetics around the world,” according to the Klass Sports news release.
Meanwhile, Love, who enters his fifth NFL season, is currently trying to make the Chiefs’ 53-man roster.
Love, a native of Fairburn, Ga., entered the league in 2010 as an undrafted free agent out of Mississippi State with the New England Patriots.
The Chiefs first signed Love on Nov. 19, 2013 and he appeared in one game in Week 12 against the San Diego Chargers before his release on Dec. 3. The Chiefs signed Love to a one-year deal on May 19.
The 27-year-old Love did not play in the first preseason game with an ankle injury, but he totaled seven tackles (four solo) in the last two preseason contests.